Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 478 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID Clear all
Completed Phase 3 Interventional

UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

NCT00111748
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide, Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 12, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

The Role of Hormones in Postpartum Mood Disorders

NCT00001481
View directory record Official record
Conditions
Postpartum Depression
Interventions
Estradiol, Placebo, Progesterone, leuprolide acetate
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 12, 2026, 12:14 AM EDT
Terminated Phase 3 Interventional

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

NCT00005834
View directory record Official record
Conditions
Multiple Myeloma
Interventions
filgrastim, cisplatin, cyclophosphamide, dexamethasone, etoposide, thalidomide
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
93
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 12, 2026, 12:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

NCT05070247
View directory record Official record
Conditions
Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
Interventions
TAK-500, Pembrolizumab, Tocilizumab, Dexamethasone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 12, 2026, 12:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition

NCT01762943
View directory record Official record
Conditions
Postpartum Depression
Interventions
Leuprolide Acetate, Micronized estradiol, Progesterone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
22 Years to 50 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Oct 12, 2026, 12:14 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus

NCT01453140
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus, Low dose IL-2, Vidaza, Cytoxan & Sirolimus
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 12, 2026, 12:14 AM EDT
Terminated Phase 2 Interventional Results available

Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement

NCT03913702
View directory record Official record
Conditions
Subacromial Impingement, Subacromial Impingement Syndrome
Interventions
Ketorolac Tromethamine, Methylprednisolone Acetate
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 12, 2026, 12:14 AM EDT
Terminated Not applicable Interventional

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

NCT02550119
View directory record Official record
Conditions
Malignant Digestive System Neoplasm, Nausea and Vomiting
Interventions
Aprepitant, Dexamethasone, Dolasetron Mesylate, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 12, 2026, 12:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

NCT05319730
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib, Sacituzumab tirumotecan, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent), Supportive care measures
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 12, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant

NCT02389517
View directory record Official record
Conditions
Plasma Cell Myeloma, Residual Disease
Interventions
Ixazomib Citrate, Lenalidomide, Dexamethasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 12, 2026, 12:14 AM EDT
Terminated Phase 2 Interventional

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

NCT05689021
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Prednisone
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 12, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

NCT04887506
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
Interventions
TAVT-45, Zytiga, Prednisone
Drug
Lead sponsor
Tavanta Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 12, 2026, 12:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Momentary Coping Prompts and Hair Steroids in College Students

NCT07782398
View directory record Official record
Conditions
Emotional Regulation, Alcohol Drinking in College, Emotional Eating, Aggression
Interventions
Momentary coping prompt, Active control message
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 12, 2026, 12:14 AM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

NCT06788912
View directory record Official record
Conditions
Lung Neoplasm Malignant
Interventions
Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Carboplatin, Pembrolizumab (adjuvant), Paclitaxel, Steroid mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
9
States / cities
Daphne, Alabama • Santa Barbara, California • Lone Tree, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 12, 2026, 12:14 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

NCT03805932
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience, Dexamethasone, Acetaminophen, Diphenhydramine, Famotidine, Aspirin
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 12, 2026, 12:14 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762716
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
BreakVax, Ipilimumab 2.5 mg, Pembrolizumab, Temozolomide (TMZ), Losartan and aspirin
Drug
Lead sponsor
BreakBio Corp
Industry
Eligibility
18 Years to 72 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 12, 2026, 12:14 AM EDT
Withdrawn Phase 2 Interventional

RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone

NCT02047552
View directory record Official record
Conditions
Functional Iron Deficiency, Trauma, Anemia
Interventions
Iron sucrose, Oxandrolone, IV iron placebo, Oxandrolone placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 12, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

NCT01478048
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Bortezomib, Dexamethasone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
42
States / cities
Corona, California • Long Beach, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 12, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00078949
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cisplatin, cytarabine, dexamethasone, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
16 Years to 65 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 12, 2026, 12:14 AM EDT
Terminated Phase 2 Interventional

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

NCT02188368
View directory record Official record
Conditions
Multiple Myeloma
Interventions
POM, Steroids, PLD, CFZ, BTZ, CLA, CY
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 12, 2026, 12:14 AM EDT
Withdrawn Phase 4 Interventional

Systemic Corticosteroids in the Perioperative Management of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT02119273
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 12, 2026, 12:14 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of Progesterone on IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones and Subjective Ratings of Stimulant Drugs

NCT01589068
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Intravenous Nicotine, Progesterone
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 12, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

NCT03367572
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride, Olanzapine, Placebo, Prochlorperazine, Quality-of-Life Assessment
Drug · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older · Female only
Enrollment
1,363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Honolulu, Hawaii • Decatur, Illinois • New Orleans, Louisiana + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 12, 2026, 12:14 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Fixation

NCT03995641
View directory record Official record
Conditions
Postoperative Pain, Pelvic Organ Prolapse, Trigger Point Injection, Sacrospinous Ligament Fixation
Interventions
marcaine and kenalog
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
21 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 12, 2026, 12:14 AM EDT